PANTOPRAZOLE Powder for solution for injection (2019)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Pantoprazole 40 mg powder for solution for injection.
Qualitative and quantitative composition
Each vial contains 40mg of pantoprazole (as sodium sesquihydrate).
Pharmaceutical form
Powder for solution for injection. White to almost white powder.
Therapeutic indications
Reflux oesophagitis. Gastric and duodenal ulcer. Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions.
Posology and method of administration
Posology Intravenous administration of Pantoprazole is recommended only if oral administration is not appropriate. Data are available on intravenous use for up to 7 days. Therefore, as soon as oral therapy ...
Contraindications
Hypersensitivity to the active substance, substituted benzimidazoles, or to any of the excipients listed in section 6.1.
Special warnings and precautions for use
In presence of alarm symptoms In the presence of any alarm symptom (e.g. significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis, anaemia or melaena) and when gastric ulcer is ...
Interaction with other medicinal products and other forms of interaction
Medicinal products with pH Dependent Absorption Pharmacokinetics Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may reduce the absorption of drugs with a gastric ...
Fertility, pregnancy and lactation
Pregnancy A moderate amount of data on pregnant women (between 300-1000 pregnancy outcomes) indicate no malformative or feto/neonatal toxicity of pantoprazole. Studies in animals have shown reproductive ...
Effects on ability to drive and use machines
Pantoprazole has no or negligible influence on the ability to drive and use machines. Adverse drug reactions such as dizziness and visual disturbances may occur (see section 4.8). If affected, patients ...
Undesirable effects
Approximately 5% of patients can be expected to experience adverse drug reactions (ADRs). The most commonly reported ADR is injection site thrombophlebitis. Diarrhoea and headache occurred in approximately ...
Overdose
There are no known symptoms of overdose in man. Systemic exposure with up to 240 mg administered intravenously over 2 minutes were well tolerated. Pantoprazole is extensively protein bound, it is not readily ...
Pharmacodynamic properties
Pharmacotherapeutic group: Drugs for acid related disorders, Proton pump inhibitors ATC code: A02BC02 Mechanism of action Pantoprazole is a substituted benzimidazole which inhibits the secretion of hydrochloric ...
Pharmacokinetic properties
General Pharmacokinetics Pharmacokinetics do not vary after single or repeated administration. In the dose range of 10 to 80 mg, the plasma kinetics of pantoprazole are linear after both oral and intravenous ...
Preclinical safety data
Pre-clinical data reveal no special hazard to humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity. In the two-year carcinogenicity studies in rats neuroendocrine ...
List of excipients
None.
Incompatibilities
This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.
Shelf life
Shelf life: 18 months. After reconstitution, or reconstitution and dilution, chemical and physical in-use stability has been demonstrated for 12 hours at 25°C. From a microbiological point of view, unless ...
Special precautions for storage
Store below 25°C. For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.
Nature and contents of container
10 ml type-I tubular colourless glass vial with grey bromobutyl rubber stopper, sealed with a red flip-off tear-off aluminium seal. Pantoprazole 40 mg powder for solution for injection is supplied in packs ...
Special precautions for disposal and other handling
A ready-to-use solution is prepared by injecting 10 ml of sodium chloride 9 mg/ml (0.9 ) solution for injection into the vial containing the powder. The appearance of the product after reconstitution is ...
Marketing authorization holder
Sun Pharmaceutical Industries Europe B.V., Polarisavenue 87, 2132 JH Hoofddorp, The Netherlands
Marketing authorization number(s)
PL 31750/0011
Date of first authorization / renewal of the authorization
01/07/2015
Date of revision of the text
24/01/2019
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
